IBL-302
IBL-302 (AMU302) is an orally available dual-signaling inhibitor of PIM and PI3K/AKT/mTOR with activity against breast cancer and neuroblastoma. IBL-302 demonstrated in vivo efficacy in a nude mouse xenograft model, inhibiting trastuzumab resistance challenges. IBL-302 also enhances the effects of common cytotoxic chemotherapy drugs cisplatin (HY-17394), doxorubicin (HY-15142A), and etoposide (HY-13629)[2][3].
Product Specifications
CAS Number
1414455-21-2
Product Name Alternative
AMU302
UNSPSC
12352005
Target
Akt; mTOR; PI3K; Pim
Type
Reference compound
Related Pathways
JAK/STAT Signaling; PI3K/Akt/mTOR
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ibl-302.html
Purity
98.21
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC1=C(C(C=C2N[S](=O)(C(C=C3)=C4)=O)=CN=C2OC)SC5=C1N=CN=C5C6=CC=C(CNC(C4=C3F)=O)S6
Molecular Formula
C25H18FN5O4S3
Molecular Weight
567.63
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Recombinant Mouse IgG1 Recombinant Mouse monoclonal Antibody
CD59 / Complement Regulatory Protein / Protectin (MACIF/2867R), CF647 conjugate, 0.1mg/mL
CD35 / CR1 (Follicular Dendritic Cell Marker) (To5), CF740 conjugate, 0.1mg/mL
